Test Method: AOAC Use Dilution
Test Conditions: 5% organic soil load, 10 minute contact time, stainless steel carrier substrates, 400 ppm hard water, 20°C exposure temperature, and 4 oz per gallon dilution.
Results:
|
No. of Carriers |
||||
|
Test Organism |
Sample | Exposed |
Positive |
Contact Time |
| Ampicillin resistant Acinetobacter baumannii (clinical isolate-Fairfax Hospital CI 02001) |
A |
10 10 |
0 |
10 minutes |
| Bactrim resistant Acinetobacter baumannii (clinical isolate-Fairfax Hospital CI 02001) |
A |
10 10 |
0 |
10 minutes |
| Bordetella bronchiseptica (ATCC 31437) |
A |
10 10 |
0 |
10 minutes |
| Cefazolin resistant Acinetobacter baumannii (clinical isolate-Fairfax Hospital CI 02001) |
A |
10 10 |
0 |
10 minutes |
| Ceftazdime resistant Acinetobacter baumannii (clinical isolate-Fairfax Hospital CI 02001) |
A |
10 10 |
0 |
10 minutes |
| Ceftriaxone resistant Acinetobacter baumannii (clinical isolate-Fairfax Hospital CI 02001) |
A |
10 10 |
0 |
10 minutes |
| Ciprofloxacin resistant Acinetobacter baumannii (clinical isolate-Fairfax Hospital CI 02001) |
A |
10 10 |
0 |
10 minutes |
| Community Associated Methicillin Resistant Staphylococcus aureus (CA-MRSA) (NRS 123, Genotype USA400) |
A |
10 10 10 |
0 |
10 minutes |
| Community Associated Methicillin Resistant Staphylococcus aureus (CA-MRSA) (NRS 384, Genotype USA300) |
A |
10 10 10 |
0 |
10 minutes |
| Corynebacterium ammoniagenes (ATCC 6871) |
A |
10 10 |
0 |
10 minutes |
| Enterobacter aerogenes (ATCC 13048) |
A |
10 10 |
0 |
10 minutes |
| Enterobacter cloacae (ATCC 23355) |
A |
10 10 |
0 |
10 minutes |
| Enterobacter cloacae (clinical isolate) |
A |
10 10 |
0 |
10 minutes |
| Enterococcus faecalis (ATCC 19433) |
A |
10 10 |
0 |
10 minutes |
| Enterococcus faecalis (clinical isolate) |
A |
10 10 |
0 |
10 minutes |
| Escherichia coli (ATCC 11229) |
A |
10 10 |
0 |
10 minutes |
| Escherichia coli (clinical isolate) |
A |
10 10 |
0 |
10 minutes |
| Escherichia coli O111:H8 (BAA-184) |
– |
– |
– |
10 minutes |
| Fusobacterium necrophorum (ATCC 27852) |
A |
10 10 |
0 |
10 minutes |
| Gentamicin resistant Acinetobacter baumannii (clinical isolate-Fairfax Hospital CI 02001) |
A |
10 10 |
0 |
10 minutes |
| Klebsiella pneumoniae subsp. pneumoniae (ATCC 13883) |
A |
10 10 |
0 |
10 minutes |
| Lactobacillus casei subsp. rhamnosus (ATCC 7469) |
A |
10 10 |
0 |
10 minutes |
| Levofloxacin resistant Acinetobacter baumannii (clinical isolate-Fairfax Hospital CI 02001) |
A |
10 10 |
0 |
10 minutes |
| Listeria monocytogenes (ATCC 35152) |
A |
10 10 |
0 |
10 minutes |
| Methicillin Resistant Staphylococcus aureus (MRSA) (ATCC 33592) |
A |
10 10 |
0 |
10 minutes |
| Pasteurella multocida (ATCC 7707) |
A |
10 10 |
0 |
10 minutes |
| Proteus mirabilis (ATCC 9921) |
A |
10 10 |
0 |
10 minutes |
| Proteus mirabilis (ATCC 25933) |
A |
10 10 |
0 |
10 minutes |
| Proteus vulgaris (ATCC 13315) |
A |
10 10 |
0 |
10 minutes |
| Pseudomonas aeruginosa PRD-10 (ATCC 15442) |
A |
60 60 60 |
0 |
10 minutes |
| Salmonella enterica subsp. enterica serotype choleraesuis (ATCC 10708) |
A |
60 60 60 |
0 |
10 minutes |
| Salmonella enterica subsp. enterica serotype paratyphi B (ATCC 8759) |
A |
10 10 |
0 |
10 minutes |
| Salmonella enterica subsp. enterica serotype pullorum (ATCC 9120) |
A |
10 10 |
0 |
10 minutes |
| Salmonella enterica subsp. enterica serotype typhi (ATCC 6539) |
A |
10 10 |
0 |
10 minutes |
| Salmonella enterica subsp. enterica serotype typhimurium (ATCC 14028) |
A |
10 10 |
0 |
10 minutes |
| Salmonella enteritidis subsp. Enterica serotype enteritidis (ATCC 13076) |
A |
10 10 |
0 |
10 minutes |
| Serratia marcescens (ATCC 8100) |
A |
10 10 |
0 |
10 minutes |
| Shigella dysenteriae (ATCC 12180) |
A |
10 10 |
0 |
10 minutes |
| Shigella flexneri Type 2b (ATCC 12022) |
A |
10 10 |
0 |
10 minutes |
| Shigella sonnei (ATCC 25931) |
A |
10 10 |
0 |
10 minutes |
| Staphylococcus aureus (ATCC 6538) |
A |
60 60 60 |
1 |
10 minutes |
| Staphylococcus aureus subsp. aureus (ATCC 33592) |
A |
10 10 |
0 |
10 minutes |
| Staphylococcus aureus (clinical isolate) |
A |
10 10 |
0 |
10 minutes |
| Staphylococcus epidermidis (ATCC 29641) |
A |
10 10 |
0 |
10 minutes |
| Staphylococcus epidermidis (clinical isolate) |
A |
10 10 |
0 |
10 minutes |
| Streptococcus pyogenes Group A (ATCC 19615) |
A |
10 10 |
0 |
10 minutes |
| Streptococcus pyogenes (clinical-flesh eating strain, BIRD M3) |
A |
10 10 |
0 |
10 minutes |
| Tobramycin resistant Acinetobacter baumannii (clinical isolate-Fairfax Hospital CI 02001) |
A |
10 10 |
0 |
10 minutes |
| Vancomycin Resistant Enterococcus faecalis (VRE) (ATCC 51575) |
A |
10 10 |
0 |
10 minutes |
| Vancomycin Intermediate Resistant Staphylococcus aureus (VISA) (HIP-5836) |
A |
10 10 |
0 |
10 minutes |
| Xanthamonas maltophilia (clinical isolate) |
A |
10 10 |
0 |
10 minutes |
| Xanthomonas axonopodis pathovar citri @ a dilution ratio of 1:13.5 (2000 ppm active quaternary) |
A |
10 10 |
0 |
– |
Conclusions: Under the conditions of this investigation, Calla® 1452 RTU demonstrated disinfectant activity against Staphylococcus aureus, Salmonella (choleraesuis) enterica, Pseudomonas aeruginosa PRD-10, Ampicillin resistant Acinetobacter baumannii, Bactrim resistant Acinetobacter baumannii, Bordetella bronchiseptica, Cefazolin resistant Acinetobacter baumannii, Ceftazdime resistant Acinetobacter baumannii, Ceftriaxone resistant Acinetobacter baumannii, Ciprofloxacin resistant Acinetobacter baumannii, Community Associated Methicillin Resistant Staphylococcus aureus (CAMRSA) (NRS 123, Genotype USA400), Community Associated Methicillin Resistant Staphylococcus aureus (CA-MRSA) (NRS384, Genotype USA300), Corynebacterium ammoniagenes, Enterobacter aerogenes, Enterobacter cloacae, Enterococcus faecalis, Escherichia coli, Fusobacterium necrophorum, Gentamicin resistant Acinetobacter baumannii, Levofloxacin resistant Acinetobacter baumannii, Klebsiella pneumonia subsp. pneumoniae, Lactobacillus casei subsp. rhamnosus, Listeria monocytogenes, Methicillin Resistant Staphylococcus aureus (MRSA), Pasteurella multocida, Proteus mirabilis (ATCC 9921), Proteus mirabilis (ATCC 25933), Proteus vulgaris, Salmonella (paratyphi B) enterica, Salmonella (pullorum) enterica, Salmonella (typhi) enterica, Salmonella (typhimurium) enterica, Salmonella (enteritidis) enterica, Serratia marcescens, Shigella dysenteriae, Shigella flexneri Type 2b, Shigella sonnei, Staphylococcus aureus subsp. aureus, Staphylococcus epidermidis, Streptococcus pyogenes Group A, Streptococcus pyogenes (clinical flesh eating strain, BIRD M3), Tobramycin resistant Acinetobacter baumannii, Vancomycin Resistant Enterococcus faecalis (VRE), and Vancomycin Intermediate Resistant Staphylococcus aureus (VISA), according to criteria established by the U.S. Environmental Protection Agency for registration and labeling of a disinfectant product as a bactericide.
Calla® 1452 RTU also demonstrated disinfectant activity against the following antibiotic resistant clinical isolates: Enterobacter cloacae, Enterococcus faecalis, Escherichia coli, Staphylococcus aureus, Staphylococcus epidermidis, and Xanthamonas maltophilia. At a dilution ratio of 1:13.5 (2000 ppm active quaternary), Calla® 1452 RTU demonstrated disinfectant activity against Xanthomonas axonopodis pathovar citri (Citrus Canker Disease).
English 
简体中文